** Shares of drug developer Acelyrin SLRN.O rise 17.05% to $2.54 premarket
** SLRN confirms that private affiliate of investor Tang Capital Partners, Concentra Biosciences, has proposed to acquire it for $3 per share in cash, a 38.2% premium to its last closing price
** The offer implies an equity value of about $300 million, according to Reuters calculations, plus a "contingent value right"
** The investor had a 5.3% stake in SLRN - filing
** Earlier this month, SLRN announced an agreement to merge with Alumis ALMS.O in an all-stock transaction
** SLRN shares have fallen nearly 38% since it reported mid-stage data from its thyroid eye disease drug in early January
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。